Unichem Laboratories (UNICHEMLAB) | Financial Analysis & Statements
Unichem Laboratories Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
5.3B
Gross Profit
2.8B
53.47%
Operating Income
-93.0M
-1.77%
Net Income
-104.7M
-1.99%
EPS (Diluted)
₹-1.49
Balance Sheet Metrics
Total Assets
35.7B
Total Liabilities
11.2B
Shareholders Equity
24.5B
Debt to Equity
0.46
Cash Flow Metrics
Free Cash Flow
-5.1B
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Unichem Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 20.6B | 16.6B | 13.0B | 12.5B | 11.9B |
| Cost of Goods Sold | 10.0B | 6.8B | 5.7B | 4.4B | 4.0B |
| Gross Profit | 10.7B | 9.7B | 7.3B | 8.1B | 7.9B |
| Gross Margin % | 51.8% | 58.7% | 56.2% | 64.7% | 66.3% |
| Operating Expenses | |||||
| Research & Development | 185.1M | 251.4M | 263.9M | 337.6M | 439.0M |
| Selling, General & Administrative | 2.5B | 2.2B | 1.6B | 1.5B | 1.6B |
| Other Operating Expenses | 1.7B | 2.8B | 2.7B | 2.3B | 2.3B |
| Total Operating Expenses | 4.5B | 5.3B | 4.6B | 4.2B | 4.3B |
| Operating Income | 1.4B | -129.9M | -1.6B | -109.0M | 72.8M |
| Operating Margin % | 6.8% | -0.8% | -11.9% | -0.9% | 0.6% |
| Non-Operating Items | |||||
| Interest Income | 28.5M | 6.7M | 5.2M | 64.8M | 229.4M |
| Interest Expense | 207.0M | 221.5M | 162.5M | 50.2M | 44.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.5B | -616.7M | -1.8B | 219.7M | 514.8M |
| Income Tax | 170.7M | 88.1M | 258.6M | -110.9M | 171.5M |
| Effective Tax Rate % | 11.0% | 0.0% | 0.0% | -50.5% | 33.3% |
| Net Income | 1.4B | -704.7M | -2.0B | 330.6M | 343.2M |
| Net Margin % | 6.7% | -4.3% | -15.5% | 2.6% | 2.9% |
| Key Metrics | |||||
| EBITDA | 2.9B | 1.2B | -150.2M | 1.2B | 1.3B |
| EPS (Basic) | ₹19.53 | ₹-10.01 | ₹-28.72 | ₹4.70 | ₹4.88 |
| EPS (Diluted) | ₹19.47 | ₹-10.01 | ₹-28.72 | ₹4.68 | ₹4.88 |
| Basic Shares Outstanding | 70405750 | 70403896 | 70413510 | 70405750 | 70405750 |
| Diluted Shares Outstanding | 70405750 | 70403896 | 70413510 | 70405750 | 70405750 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Unichem Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 895.8M | 1.5B | 1.8B | 1.1B | 774.6M |
| Short-term Investments | 328.8M | 13.4M | 15.4M | 2.6B | 2.4B |
| Accounts Receivable | 7.8B | 6.1B | 5.9B | 5.0B | 2.5B |
| Inventory | 9.9B | 7.0B | 6.3B | 6.0B | 5.4B |
| Other Current Assets | 1.4B | 2.2B | 1.9B | 1.7B | 2.6B |
| Total Current Assets | 20.3B | 16.9B | 15.9B | 16.4B | 13.8B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 12.8B | 11.9B | 12.6B | 9.9B | 8.8B |
| Goodwill | 218.0M | 30.9M | 30.9M | 30.9M | 30.9M |
| Intangible Assets | 187.0M | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 248.0M | 214.5M | 187.2M | 163.0M | 145.2M |
| Total Non-Current Assets | 15.4B | 14.8B | 16.0B | 16.7B | 17.5B |
| Total Assets | 35.7B | 31.7B | 31.9B | 33.2B | 31.3B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.0B | 3.0B | 2.9B | 1.8B | 2.1B |
| Short-term Debt | 3.7B | 1.9B | 2.4B | 2.5B | 1.0B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 229.9M | 561.4M | 518.9M | 526.5M | 566.2M |
| Total Current Liabilities | 9.9B | 7.1B | 6.4B | 5.5B | 5.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 860.0M | 623.7M | 751.4M | 1.0B | 143.1M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 137.0M |
| Other Non-Current Liabilities | 6.4M | 8.7M | 11.0M | 46.9M | 46.9M |
| Total Non-Current Liabilities | 1.3B | 990.5M | 1.2B | 1.5B | 631.2M |
| Total Liabilities | 11.2B | 8.1B | 7.6B | 7.0B | 5.7B |
| Equity | |||||
| Common Stock | 140.8M | 140.8M | 140.8M | 140.8M | 140.8M |
| Retained Earnings | 24.6B | 23.4B | 24.0B | 25.1B | 25.0B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 24.5B | 23.6B | 24.4B | 26.2B | 25.6B |
| Key Metrics | |||||
| Total Debt | 4.6B | 2.5B | 3.1B | 3.5B | 1.2B |
| Working Capital | 10.4B | 9.9B | 9.5B | 10.9B | 8.7B |
Balance Sheet Composition
Unichem Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.5B | -616.7M | -1.8B | 219.7M | 514.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 21.2M | 30.8M | 10.5M | 28.5M | 28.3M |
| Working Capital Changes | -2.9B | -958.3M | -1.5B | -3.4B | -467.2M |
| Operating Cash Flow | -1.2B | -1.3B | -3.1B | -3.1B | -106.9M |
| Investing Activities | |||||
| Capital Expenditures | -1.4B | -136.1M | -379.4M | -1.3B | -2.9B |
| Acquisitions | -844.5M | - | 0 | 0 | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 13.6M | 652.4M | 2.4B | 2.0B | 1.9B |
| Investing Cash Flow | -2.4B | 498.3M | 2.0B | 776.4M | -1.0B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -3.4M | -2.1M | -282.5M | -283.6M | -286.6M |
| Debt Issuance | 503.9M | - | 0 | 1.2B | 0 |
| Debt Repayment | -256.6M | -256.6M | -256.6M | -95.2M | 0 |
| Financing Cash Flow | 2.1B | -786.9M | -616.1M | 2.0B | -1.1B |
| Free Cash Flow | -1.4B | -58.5M | -1.3B | -3.9B | -2.5B |
| Net Change in Cash | -1.5B | -1.6B | -1.7B | -360.5M | -2.3B |
Cash Flow Trend
Unichem Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
8.91
Price to Book
1.08
Price to Sales
1.18
PEG Ratio
0.02
Profitability Ratios
Profit Margin
13.32%
Operating Margin
2.60%
Return on Equity
5.61%
Return on Assets
3.85%
Financial Health
Current Ratio
1.99
Debt to Equity
20.62
Beta
-0.21
Per Share Data
EPS (TTM)
₹41.78
Book Value per Share
₹346.08
Revenue per Share
₹314.41
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| UNICHEMLAB | 26.2B | 8.91 | 1.08 | 5.61% | 13.32% | 20.62 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





